Crispr Theraputics
One sentence overview: Crispr Theraputics is a discovery-phase pharmaceutical Crispr working to develop therapies based on CRISPR–Cas9 gene editing technology.
Crispr Ticker : CRSP
6/3/2020 Stock Price : $64.95
6/3/2020 Market Cap : $4.0 billion
Total Shares Outstanding Recent Quarterly Report : 61 million shares
| Jan 2020 | March Low | Apr 30 | 6/3/2020 | YTD % | |
| Crispr | $59 | $34 | $49 | $65 | 10% |
| S&P 500 | 3231 | 2237 | 2912 | 3123 | -4% |
Crispr Investor Relations Page
http://ir.crisprtx.com/investor-overview
Crispr SEC Page
https://www.sec.gov/cgi-bin/browse-edgar?CIK=crsp&owner=…
Crispr Glassdoor Ratings
https://www.glassdoor.com/Overview/Working-at-CRISPR-Therape…
Crispr Overview
Crispr Medicine is one of three companies (Editas Medicine EDIT and Intellia Theraputics NTLA) using Crispr-Cas9 technology. For an explanation for Crispr-Cas9 technology go here:
https://www.livescience.com/58790-crispr-explained.html
Products
The next slides are from a June 2020 presentation from their Investor Relations. It should be pointed out Crispr products presented in the slides are at least 5 years away from the commercial market. Clinical trials typically take about 5 years to complete.
Financials
Competition
Editas Medicine EDIT and Intellia Theraputics NTLA are the two other companies using Crispr-Cas9 technology.
Future Outlook
Crispr work on sickle cell anemia is promising. However, clinical trials have long time horizon and FDA approval will take years.
Risks
Unsuccessful clinical trials would result in starting over. To maintain an ongoing entity, additional stock offerings will be done and therefore dilute current shareholder positions.
Disclaimer: I do not have any formal recommendation for or against this stock, so don’t buy or sell stocks based solely on what you read.
Interested in receiving a weekly recap of reviewed stocks? Sign up.
